MedPath

Effects of Polyphenols of Pomegranate Fruit Peel Extract on Inflammation and Oxidative Stress in Metabolic Syndrome

Not Applicable
Active, not recruiting
Conditions
Metabolic Syndrome
Interventions
Drug: Placebo
Dietary Supplement: Polyphenols of pomegranate fruit peel extract (PoPex)
Registration Number
NCT05915117
Lead Sponsor
University of Banja Luka
Brief Summary

The purpose of this study is to evaluate the effects of polyphenols of pomegranate fruit peel extract compared to placebo on oxidative stress and inflammation in overweight and obese subjects with metabolic syndrome.

Detailed Description

This is a Phase 3, randomized, double-blind, placebo-controlled evaluation of the efficacy of polyphenols of pomegranate fruit peel extract on oxidative stress and inflammation in overweight and obese subjects with metabolic syndrome.

Study site: a single study center (Primary Health Care Institution in Banja Luka, as recruiter center) as recruitment center including Center for Biomedical Research, Faculty of Medicine University of Banja Luka, as local laboratory and coordinator.

Sample size: 60 subjects, randomized in a 1:1 allocation ratio.

Primary objectives are to investigate an effect of polyphenols pomegranate fruit peel extract on: Anthropometric parameters such as body mass index, and arterial blood pressure, glycemia, lipoprotein profile, homeostatic model assessment for insulin resistance (HOMAIR), homocysteine, vitamin B complex: folic acid, vitamin B6, vitamin B9 and vitamin B12.

2. To investigate the effects polyphenols from pomegranate fruit peel extract has on impact on lipid peroxidation index, nitric oxide metabolites, hydrogen peroxide (H2O2), superoxide anion radical (O2-), and glutathione (GSH), catalase (CAT) and superoxide dismutase (SOD).

3. Proinflammatory markers interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), high sensitive CRP (hsCRP), leptin, resistin ,vaspin, chemerin, lipokalin-2 and katepsin .

4. Anti-infammatory markers IL-5, IL-10, IL-12 ,adiponectin and omentin.

Treatments arms:

Polyphenols of pomegranate fruit peel extract (PoPeEx) (500 mg/day) Placebo

Treatment duration :

8 weeks

Assessment - clinical and laboratory sampling:

Informed consent and Screening - 7 days prior to randomization

Study visits (V):

V1 - Randomization and Enrollment (Baseline) V2 - 4 weeks after Baseline V3 - 8 weeks after Baseline.

No interim analysis is planned. The analysis will be performed at the end of the study after data review and freezing of the database according to the intent to treat principle.

- Page 2 of 6 \[DRAFT\] -

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria

Informed consent signed Adults of 20 to 60 years BMI ≥ 25.00 kg/m2

Met criteria for metabolic syndrome such as visceral obesity( for men ≥ 94 cm and ≥ 80 cm for women) and at least two risk factors:

  1. TG ≥ 1,7 mmol/l, or present therapy for dyslipidemia
  2. HDL <1,03 mmol/l men, <1,29 mmol/l women
  3. Arterial blood pressure ≥130/85 mmHg
  4. Glycemia ≥ 5.6 mmol/l and < 6.9 mmol/l
Exclusion Criteria

Subjects with malignant and other acute and chronic infectious and non-infectious disease requiring active pharmacotherapy.

Subjects with with insulin dependent diabetes mellitus or subjects with insulin independent diabetes mellitus taking oral hypoglycemic therapy Subjects with uncontrolled chronic cardiovascular, endocrine, autoimmune, psychiatric, and autoimmune diseases or other condition based on the investigator judgement.

Non adherent subject Systematic use of corticosteroids Pregnant or lactating women Chronic use of supplements (omega 3 unsaturated acids, silymarin, mineral-vitamin supplements) Participation in any other interventional study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboAll subjects will treated only with PoPex placebo capsules/orally over 8 weeks
Polyphenols of pomegranate fruit peel extract (PoPex)Polyphenols of pomegranate fruit peel extract (PoPex)All subjects will treated only with PoPex in total daily dosis of 500 mg/orally over 8 weeks.
Primary Outcome Measures
NameTimeMethod
Change in proinflammatori parametars:interleukin-6 (IL-6), tumor necrosis factor-α (TNF- α), high sensitive CRP (hsCRP), leptin, resistin ,vaspin, chemerin ,lipokalin -2 and katepsinFrom Baseline and after 8 weeks

ELISA assey

Change in antiinflammatori parametars:interleukin -5 (IL-5) ,interleukin-10(IL-10), interleukin-12 (IL-12) ,adiponectin and omentinFrom Baseline and after 8 weeks

ELISA assey

Change in oxidative stress biomarkers levels: lipid peroxidation index, nitric oxide metabolites, hydrogen peroxide (H2O2), superoxide anion radical (O2-), and glutation (GSH), catalasis(CAT) and superoxid dismutasis(SOD).From Baseline and after 8 weeks

ELISA assey

Secondary Outcome Measures
NameTimeMethod
Change in serum levels of vitamin B6-piridoxin ,vitamin B9-folic acid ,vitamin B12-cianocobalaminFrom Baseline, after 4 and 8 weeks

Microparticle enzyme immunoassey

Change in serum levels of liver function testsFrom Baseline,after 4 and after 8 weeks

IFCC,reference method with pyridoxyl phosphate

Change in systolic and diastolic blood presureFrom Baseline and after 8 weeks

mm/HG

Change in inflammation marker level : high sensitivity CRP Turbid mertic testFrom Baseline and after 8 weeks

Turbid metric test

Change in serum levels homocysteinFrom Baseline,after 4 and 8 weeks

Detection by fluoroscence polarization immunoassay

Change in serum levels of glycemia, insulinemiaFrom Baseline,after 4 and after 8 weeks

glycemia-hexokinase method,insulinemia-ultrasensitivity test,immunoenzyme test:"sandwich"

Change in body weightFrom Baseline and after 8 weeks

weight ( kg)

Change in total choleterol (TC), low -density lipoprotein ( LDL), high-density lipoprotein (HDL) and trglicerides Turbid mertic testFrom Baseline,after 4 and 8 weeks

Clinical biochemistry (colorimetric) test and results will be expressed in mmol/l

Trial Locations

Locations (1)

Public Health Institution Dom zdravlja Banja Luka

🇧🇦

Banja Luka, Republic Of Srpska, Bosnia and Herzegovina

© Copyright 2025. All Rights Reserved by MedPath